Glaxo/Vertex HIV protease inhibitor shows reduction in viral load.
Executive Summary
GLAXO/VERTEX HIV PROTEASE INHIBITOR 141W94 SHOWS 99% REDUCTION IN VIRAL LOAD at a dose level of 1200 mg twice daily, according to results of a Phase I/II study presented Sept. 16 at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy in New Orleans. The study also showed a median increase of 110 CD4 cells over baseline at 1200 mg b.i.d., the highest dose tested.